Regulatory Approval

26th OCTOBER 2009


                           ECO Animal Health Group plc

        POSITIVE OPINION ON NEW AIVLOSIN® PRODUCT FOR PHEASANTS IN EUROPE


ECO  Animal  Health  Group plc is pleased to announce that  its  subsidiary  ECO
Animal  Health Limited (ECO) has received a positive opinion from  the  European
Medicines  Evaluation Agency (EMEA) for Aivlosin granules for oral solution  for
medicated drinking water for pheasants throughout Europe.

This  positive opinion will allow Aivlosin to be marketed in Europe for  use  in
pheasants  for  the  treatment  of  respiratory  disease  caused  by  Mycoplasma
gallisepticum,  one  of  the  most economically  important  diseases  of  farmed
pheasants.

The  UK and France account for the vast majority of intensively reared pheasants
in  the  EU,  with  over 30 million birds being reared in  these  two  countries
annually.
ECO   will  market  Aivlosin  for  pheasants  directly  to  specialist   poultry
veterinarians in the UK.

Aivlosin  granules for oral solution, as the first authorised  product  for  the
treatment of this condition, will fulfil a currently unmet need in the market by
providing  a  safe and effective solution for the treatment of reared  pheasants
and breeding stock.

The  EMEA's  positive opinion marks another important step in  ECO's  continuing
development  of Aivlosin as a global veterinary product. It will extend  further
the  marketing reach of Aivlosin, ECO's patented macrolide antibiotic, which  is
used for the treatment of respiratory and enteric diseases in pigs and poultry.


Contacts:
ECO  Animal Health Group plc                    Marc Loomes      020 8447 8899

Spiro Financial                                 Anthony Spiro    020 8336 6196

Cenkos  Securities plc                          Stephen  Keys    020 7397 8926
(Nominated Adviser)

ECO  Animal  Health Group plc is a leader in the development,  registration  and
marketing of pharmaceutical products for animals. Our products for these  global
growth markets promote well-being. Our financial goals are achieved through  the
careful  and  responsible  application of science  to  generate  value  for  our
shareholders.